We'll now take questions....
Third doctor was very compelling.Bringing out the big guns commenting from a physician perspective about experiences with leronlimab and updates on publications. Questions have been asked about why they've been quiet, but now they're going out there and vouching for the drug. Seems compelling.
Shot down on getting EUA in both countries. They want to see S/C results. No surprise there.I don't know, I dont think this is gonna play well. We've all heard the anecdotal already.
This CC seems like a mistake to have so for, hope I'm wrong but bad news probably coming to make it even worse
Have never heard from the last two doctors before like thisI don't know, I dont think this is gonna play well. We've all heard the anecdotal already.
This CC seems like a mistake to have so for, hope I'm wrong but bad news probably coming to make it even worse
Unfortunately yes, its gonna bomb in the short term.Well, the AF hit piece just writes itself at this point. Still optimistic about the long-term options here, but short term will be brutal
Agreed. 100% this.Oof, definitely going to drop soon.
Uplisting will have review of application completed next week. They don't sound optimistic to be honest.
"Sometime this year"Sounds like I should have dumped it all at $5 and just assumed it would dump to sub $3 at some point. Did they give an update on S/C and when that could happen?
SMH. Limit order already set for $4. Hopefully it doesn’t tank too early."Sometime this year"
That’s well above the count for “interim” results, right?Over 210 patients right now
Yes, but in the back of my mind, I'm always going to be worried that if they only deliver interim results, they wont be rewarded even if they are good.That’s well above the count for “interim” results, right?
He is the doctor that is credited with single-handedly getting patients to enter the trials when enrollment had come to a standstill. Him being a buddy of Scott Kelly and now getting hired calls into question his motivations.Also sounds like that last doctor is now on the payroll unless I missed something. Not sure that's a good thing or not...
I would be shocked if this hits.SMH. Limit order already set for $4. Hopefully it doesn’t tank too early.
Still waiting on S/C results, and lowered probability on the uplisting option.I wasn't expecting much and Im still bummed out. There was nothing announced to be excited about.
I'm with you. Gilead's biggest strength is have NP as the CEO of CYDY. He is completely lost, and the worse part about it is that he doesn't understand that he's in over his head. Atleast then he would hire people that could get things done.Still waiting on S/C results, and lowered probability on the uplisting option.
What I'm most discouraged about is that the FDA and MHRA had no intention of greenlighting a drug for EUA for mild/moderate populations, which means the exercise has been pointless. How could they be unaware of this, spending all this time and blowing so much smoke about it, while all the while had they known enough about what the FDA was looking for they'd have known there was basically no shot.
That's a big flaw imo. Anyone see things differently?
Maybe, maybe not. Honestly, my fault for forgetting the call. At this point, just more stuff I’d rather own. Order’s in for $4 limit. If it doesn’t hit, ride it out.I would be shocked if this hits.
The problem as I see it is there was a short term bubble introduced by the tilting at windmills NP has lead lately. A better use of his time, and company resources, over the past few months would've been a focused approach regarding the S/C trial, enrollment, and results at which point FDA could be consulted and uplisting could follow.Maybe, maybe not. Honestly, my fault for forgetting the call. At this point, just more stuff I’d rather own. Order’s in for $4 limit. If it doesn’t hit, ride it out.
Disagree on your last sentence. They don't need a $20M CEO. They just need competence. There are a lot of very good people that have been in the industry that would take on a job like this.The problem as I see it is there was a short term bubble introduced by the tilting at windmills NP has lead lately. A better use of his time, and company resources, over the past few months would've been a focused approach regarding the S/C trial, enrollment, and results at which point FDA could be consulted and uplisting could follow.
INstead, he took a shotgun approach spreading out resources into mild-moderate studies, EUA in with results in a study the FDA didn't care about, and started the uplisting process with a stock price inflated on the hopes of getting an EUA quickly, or FDA approval.
FDA approval still seems likely down the road for monotherapy, and other indications are promising, but man the timeline for returns has been expanded by months at least. So for those of us locked in, it'll be end of 2020 at this point before we can start to see some promising results. You could tell NP knew the situation as he was short, abrupt, and frustrated on the call.
The company is indebted to him to get it this far, but really it needs a steadier hand far more familiar with the process than NP is at the current moment. However, for a company without an approved drug, they're unlikely to find anyone better to take the helm at this point.
On this series of tweets, I think he has a point.https://twitter.com/adamfeuerstein/status/1306341325273534466
This joker will not relent. Why does he hate them so much?
He's not wrong on a lot of this.https://twitter.com/adamfeuerstein/status/1306341325273534466
This joker will not relent. Why does he hate them so much?
By all means, the board should wish NP the best, thanks for the memories, and bring someone else in if they can find a quality person who can turn this around.Disagree on your last sentence. They don't need a $20M CEO. They just need competence. There are a lot of very good people that have been in the industry that would take on a job like this.
The tweet didn't link like I was expecting.On this series of tweets, I think he has a point.
NP did admit that no EUA was submitted. That is not how he promoted it.
I'm a big AF critic, but I think he's not too far off here. I feel like while NP has meant the best over the past few months, I'm left with just words and a lot of poor decisions and smoke and mirrors in terms of what he's offered in terms of guidance and direction for the company. I think he should step down and let someone else bring Cytodyn into the next chapter and beyond.
I honestly don't think there is malice or intentional fraud. NP is just incompetent.The tweet didn't link like I was expecting.
I wanted to call attention to this line in particular
"I've covered a lot of sick and twisted biotech companies in my 20 years on the beat, CytoDyn scrapes the bottom."
I didn't hear what you did here. Can you expand on this? Aren't we still expecting interim results in October?So for those of us locked in, it'll be end of 2020 at this point before we can start to see some promising results. You could tell NP knew the situation as he was short, abrupt, and frustrated on the call.